Cytosorbents Corporation, a medical device company, has been making strides in the research, development, and commercialization of its blood purification technology platform across the globe. Built on a proprietary adsorbent and porous polymer technology, the company's flagship product, CytoSorb, is an extracorporeal cytokine adsorber used for adjunctive therapy in sepsis treatment, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplants. In addition to this, Cytosorbents is also engaged in developing various other devices that offer adjunctive therapy in critical care applications, such as VetResQ and CytoSorb-XL, and specialized devices for the removal of contaminants in blood products and toxic chemicals from the blood, including HemoDefend, K+ontrol, ContrastSorb, BetaSorb, DrugSorb, and DrugSorb-ATR. The company, which was formerly known as MedaSorb Technologies Corporation, changed its name to Cytosorbents Corporation in May 2010 and is headquartered in Princeton, New Jersey.